Detalhe da pesquisa
1.
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
Blood
; 139(9): 1340-1358, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788382
2.
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Cytotherapy
; 22(7): 369-376, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32303428
3.
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.
Blood Adv
; 6(20): 5641-5654, 2022 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35486482
4.
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity.
Cell Rep
; 40(3): 111115, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858552
5.
The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.
Blood Adv
; 5(16): 3152-3162, 2021 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424320
6.
Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
Blood Adv
; 3(8): 1255-1266, 2019 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30987970
7.
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
Leuk Res
; 118: 106872, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35640397